Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin Special Drug Use-Results Survey in Chronic Sialorrhea
jRCT2031260082Recruiting
- Sponsor
- Teijin Pharma
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in hypersalivation, sponsored by Teijin Pharma. Primary endpoint: Incidence of aspiration pneumonia. Started Apr 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
hypersalivation
Beyond the preview
Go deeper on jRCT2031260082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260082.